|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US20130072665A1
(en)
*
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JO3672B1
(ar)
*
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
*
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
MY192182A
(en)
|
2009-06-26 |
2022-08-04 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
DK3622815T3
(da)
|
2009-07-08 |
2023-06-26 |
Kymab Ltd |
Gnavermodeller og terapeutiske molekyler
|
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
IN2012DN03824A
(https=)
|
2009-10-30 |
2015-08-28 |
Merck Sharp & Dohme |
|
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
JO3274B1
(ar)
|
2009-12-24 |
2018-09-16 |
Regeneron Pharma |
أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
|
|
JP5932670B2
(ja)
*
|
2010-03-11 |
2016-06-08 |
ライナット ニューロサイエンス コーポレイション |
ｐＨ依存性の抗原結合を有する抗体
|
|
AU2011286024B2
(en)
*
|
2010-08-02 |
2014-08-07 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
CN103261230A
(zh)
*
|
2010-12-22 |
2013-08-21 |
霍夫曼-拉罗奇有限公司 |
抗pcsk9抗体及使用方法
|
|
SG192117A1
(en)
*
|
2011-01-28 |
2013-08-30 |
Sanofi Sa |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
|
EP2481758A1
(en)
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
|
US8337530B2
(en)
|
2011-03-09 |
2012-12-25 |
Zimmer Spine, Inc. |
Polyaxial pedicle screw with increased angulation
|
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
RU2014100111A
(ru)
|
2011-06-10 |
2015-07-20 |
МЕДИММЬЮН, ЭлЭлСи |
МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
|
|
AR087329A1
(es)
|
2011-06-17 |
2014-03-19 |
Regeneron Pharma |
Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
|
|
TWI687439B
(zh)
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
|
BR112014000392A2
(pt)
*
|
2011-07-14 |
2017-02-21 |
Pfizer |
tratamento com anticorpos anti-pcsk9
|
|
AR087305A1
(es)
*
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087715A1
(es)
*
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
HUE069234T2
(hu)
|
2011-09-16 |
2025-02-28 |
Regeneron Pharma |
Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
ITPC20110013U1
(it)
|
2011-10-07 |
2013-04-08 |
Giovanni Merli |
Struttura di protezione superiore veicoli.
|
|
HRP20201370T1
(hr)
|
2011-11-07 |
2020-11-27 |
Medimmune Limited |
Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
|
|
KR20230143201A
(ko)
|
2011-11-30 |
2023-10-11 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
JP6635655B2
(ja)
|
2011-12-08 |
2020-01-29 |
アムジエン・インコーポレーテツド |
ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
|
|
KR102063028B1
(ko)
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ａｎｇ2 항체를 함유하는 안정화된 제형
|
|
NZ626242A
(en)
*
|
2012-01-31 |
2017-02-24 |
Regeneron Pharma |
Anti-asic1 antibodies and uses thereof
|
|
EP3539374A1
(en)
|
2012-03-16 |
2019-09-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
EP2825036B1
(en)
|
2012-03-16 |
2018-05-02 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US20130281355A1
(en)
*
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
*
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
EP2861624A1
(en)
*
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
US9540449B2
(en)
|
2012-08-13 |
2017-01-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-PCSK9 antibodies with pH-dependent binding characteristics
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
SG10201709559PA
(en)
|
2012-08-24 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Fcγriib-specific fc region variant
|
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
ES2860954T3
(es)
|
2012-11-21 |
2021-10-05 |
Amgen Inc |
Dispositivo de administración de fármacos
|
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
|
US20150335615A1
(en)
*
|
2013-01-04 |
2015-11-26 |
Toshihisa Kawai |
Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
|
|
WO2014107739A1
(en)
*
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
WO2014150983A2
(en)
*
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
|
US10646664B2
(en)
|
2013-03-15 |
2020-05-12 |
Amgen Inc. |
Body contour adaptable autoinjector device
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
TWI614041B
(zh)
|
2013-03-15 |
2018-02-11 |
安美基公司 |
用於注射器之匣盒
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2014149357A1
(en)
|
2013-03-22 |
2014-09-25 |
Amgen Inc. |
Injector and method of assembly
|
|
CN105246914B
(zh)
|
2013-04-02 |
2021-08-27 |
中外制药株式会社 |
Fc区变体
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI682780B
(zh)
*
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
ES2901400T3
(es)
*
|
2013-06-07 |
2022-03-22 |
Regeneron Pharma |
Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9
|
|
US10494442B2
(en)
*
|
2013-06-07 |
2019-12-03 |
Sanofi Biotechnology |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
AU2014330922A1
(en)
|
2013-10-01 |
2016-03-03 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
ES2914978T3
(es)
*
|
2013-10-11 |
2022-06-20 |
Sanofi Biotechnology |
Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
|
|
SG11201602876WA
(en)
|
2013-10-24 |
2016-05-30 |
Amgen Inc |
Injector and method of assembly
|
|
CA3168888A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
|
ES2864350T3
(es)
*
|
2013-11-12 |
2021-10-13 |
Regeneron Pharma |
Pautas posológicas para uso con inhibidores de PCSK9
|
|
CN118105480A
(zh)
*
|
2013-11-12 |
2024-05-31 |
赛诺菲生物技术公司 |
用于与pcsk9抑制剂一起使用的给药方案
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
WO2015093949A2
(en)
*
|
2013-12-17 |
2015-06-25 |
Aimm Therapeutics B.V. |
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
EA201691320A1
(ru)
|
2014-02-14 |
2016-11-30 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
AU2015256082C1
(en)
|
2014-05-07 |
2020-09-10 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
|
CN111840696B
(zh)
|
2014-06-03 |
2022-12-20 |
安姆根有限公司 |
可控制药物递送系统和使用方法
|
|
WO2015200438A1
(en)
*
|
2014-06-24 |
2015-12-30 |
Eleven Biotherapeutics, Inc. |
High affinity antibodies against pcsk9
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
DE202015009006U1
(de)
|
2014-07-15 |
2016-08-19 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
EP2975059A1
(en)
|
2014-07-15 |
2016-01-20 |
Kymab Limited |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
EP4328245A3
(en)
|
2014-07-15 |
2024-06-05 |
Kymab Ltd. |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
CA2955304C
(en)
*
|
2014-07-16 |
2023-12-12 |
Sanofi Biotechnology |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
WO2016020798A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
US11554181B2
(en)
|
2014-09-05 |
2023-01-17 |
The University Of North Carolina At Charlotte |
Tumor specific antibody conjugates and uses therefor
|
|
CN107001461A
(zh)
|
2014-09-16 |
2017-08-01 |
瑞泽恩制药公司 |
抗胰高血糖素抗体及其使用方法
|
|
WO2016046684A1
(en)
|
2014-09-23 |
2016-03-31 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
EP3206739B1
(en)
|
2014-10-14 |
2021-12-01 |
Amgen Inc. |
Drug injection device with visual and audio indicators
|
|
WO2016065181A1
(en)
|
2014-10-23 |
2016-04-28 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
EP3848072A1
(en)
*
|
2014-12-19 |
2021-07-14 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
US11357916B2
(en)
|
2014-12-19 |
2022-06-14 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
CN105461809B
(zh)
*
|
2015-02-11 |
2018-10-12 |
康融东方（广东）医药有限公司 |
Pcsk9抗体、其药物组合物及其用途
|
|
JP6484345B2
(ja)
|
2015-02-17 |
2019-03-20 |
アムジエン・インコーポレーテツド |
固定及び／または戻りが真空によって支援された薬物送達装置
|
|
EA039310B1
(ru)
*
|
2015-02-26 |
2022-01-12 |
Санофи Байотекнолоджи |
Способы снижения сердечно-сосудистого риска
|
|
WO2016138434A1
(en)
|
2015-02-27 |
2016-09-01 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
|
EP3271405A1
(en)
*
|
2015-03-20 |
2018-01-24 |
Aarhus Universitet |
Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
|
|
EP4679095A3
(en)
|
2015-05-18 |
2026-05-06 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
WO2016187354A1
(en)
*
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
CN106084058B
(zh)
*
|
2015-07-15 |
2019-08-27 |
北京天广实生物技术股份有限公司 |
抗人pcsk9单克隆抗体
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
|
CN106589127A
(zh)
*
|
2015-10-16 |
2017-04-26 |
钜川生物医药 |
一种pcsk9抗体及其制备方法和应用
|
|
CN105348390B
(zh)
*
|
2015-10-26 |
2018-08-28 |
北京智仁美博生物科技有限公司 |
抗人pcsk9单克隆抗体
|
|
CN106810609A
(zh)
*
|
2015-11-27 |
2017-06-09 |
苏州君盟生物医药科技有限公司 |
抗pcsk9抗体及其应用
|
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
EP3398968B1
(en)
*
|
2015-12-31 |
2024-06-12 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pcsk9 antibody, antigen-binding fragment thereof, and medicinal application thereof
|
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
MA44234B1
(fr)
*
|
2016-02-17 |
2023-10-31 |
Regeneron Pharma |
Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
|
|
MA43734A
(fr)
|
2016-03-03 |
2018-11-28 |
Regeneron Pharma |
Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
|
|
DK3429663T3
(da)
|
2016-03-15 |
2020-09-28 |
Amgen Inc |
Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
|
|
WO2017163049A1
(en)
|
2016-03-21 |
2017-09-28 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
|
US11066464B2
(en)
|
2016-03-21 |
2021-07-20 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
|
CN107266575B
(zh)
*
|
2016-04-07 |
2021-12-24 |
天士力生物医药股份有限公司 |
前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
|
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
AU2017263558B2
(en)
|
2016-05-13 |
2022-12-22 |
Amgen Inc. |
Vial sleeve assembly
|
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
US11541176B2
(en)
|
2016-06-03 |
2023-01-03 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
|
CN107474140B
(zh)
*
|
2016-06-08 |
2022-06-03 |
常州博嘉生物医药科技有限公司 |
Pcsk9特异性的结合蛋白mv072及其应用
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
EP3478342B1
(en)
|
2016-07-01 |
2025-03-12 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
|
|
US11858996B2
(en)
|
2016-08-09 |
2024-01-02 |
Kymab Limited |
Anti-ICOS antibodies
|
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
KR20190049866A
(ko)
|
2016-09-20 |
2019-05-09 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 항-ｐｃｓｋ９ 항체
|
|
WO2018054240A1
(en)
*
|
2016-09-20 |
2018-03-29 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pcsk9 antibodies
|
|
EP3522918A1
(en)
|
2016-10-06 |
2019-08-14 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
WO2018075621A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Vanderbilt University |
Human orthopoxvirus antibodies and methods of use therefor
|
|
US20190248888A1
(en)
|
2016-10-20 |
2019-08-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of lowering blood glucose levels
|
|
US20200261643A1
(en)
|
2016-10-25 |
2020-08-20 |
Amgen Inc. |
On-body injector
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
CN108239150A
(zh)
|
2016-12-24 |
2018-07-03 |
信达生物制药(苏州)有限公司 |
抗pcsk9抗体及其用途
|
|
AU2018210301A1
(en)
|
2017-01-17 |
2019-08-01 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
|
CN106749670B
(zh)
|
2017-01-22 |
2018-06-12 |
北京东方百泰生物科技有限公司 |
抗pcsk9单克隆抗体
|
|
CN108424457B
(zh)
*
|
2017-02-13 |
2021-06-01 |
成都金洛克锶生物技术有限公司 |
针对pcsk9抗体与检测试剂盒的制备及其用途
|
|
WO2018151890A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
|
CA3052204A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
EP3592403B1
(en)
|
2017-03-06 |
2025-08-20 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
|
US11571511B2
(en)
|
2017-03-07 |
2023-02-07 |
Amgen Inc. |
Insertion mechanism and method of inserting a needle of a drug delivery device
|
|
AU2018230486B2
(en)
|
2017-03-09 |
2023-05-11 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
ES3023742T3
(en)
|
2017-03-28 |
2025-06-03 |
Amgen Inc |
Plunger rod and syringe assembly system
|
|
US9989519B1
(en)
*
|
2017-05-04 |
2018-06-05 |
Clayton Pharmaceuticals, LLC |
Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD)
|
|
US11590294B2
(en)
|
2017-06-08 |
2023-02-28 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
JP7200134B2
(ja)
|
2017-06-08 |
2023-01-06 |
アムジエン・インコーポレーテツド |
トルク駆動式薬物送達デバイス
|
|
TW201904608A
(zh)
*
|
2017-06-09 |
2019-02-01 |
法商賽諾菲生物技術公司 |
藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
|
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
JP7195276B2
(ja)
|
2017-06-22 |
2022-12-23 |
アムジエン・インコーポレーテツド |
デバイス起動による衝突／衝撃の低減
|
|
WO2018237225A1
(en)
|
2017-06-23 |
2018-12-27 |
Amgen Inc. |
Electronic drug delivery device comprising a cap activated by a switch assembly
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
IL270784B2
(en)
|
2017-07-14 |
2023-11-01 |
Amgen Inc |
Needle insertion-extraction system with a double torsion spring system
|
|
JP7649105B2
(ja)
|
2017-07-21 |
2025-03-19 |
アムジエン・インコーポレーテツド |
薬物容器のためのガス透過性シーリング部材及び組立方法
|
|
US11617837B2
(en)
|
2017-07-25 |
2023-04-04 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
|
MA49676A
(fr)
|
2017-07-25 |
2020-06-03 |
Amgen Inc |
Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
|
|
MA49838A
(fr)
|
2017-08-09 |
2020-06-17 |
Amgen Inc |
Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
|
|
EP3668567B1
(en)
|
2017-08-18 |
2026-02-18 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
US12605469B2
(en)
|
2017-10-02 |
2026-04-21 |
The University Of North Carolina At Charlotte |
Tumor specific antibody conjugates and uses therefor
|
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
|
ES2971450T3
(es)
|
2017-10-06 |
2024-06-05 |
Amgen Inc |
Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
|
|
US11464903B2
(en)
|
2017-10-09 |
2022-10-11 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
|
IL273582B2
(en)
|
2017-11-03 |
2024-12-01 |
Amgen Inc |
Systems and approaches for sterilizing a drug delivery device
|
|
EP3706830B1
(en)
|
2017-11-06 |
2024-08-07 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
|
EP3707075A1
(en)
|
2017-11-06 |
2020-09-16 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
|
MA50557A
(fr)
|
2017-11-10 |
2020-09-16 |
Amgen Inc |
Pistons pour dispositifs d'administration de médicament
|
|
EP4640703A3
(en)
|
2017-11-14 |
2026-04-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
MX2020005066A
(es)
|
2017-11-16 |
2020-08-20 |
Amgen Inc |
Autoinyector con deteccion de detencion y punto final.
|
|
JP7370969B2
(ja)
|
2017-11-16 |
2023-10-30 |
アムジエン・インコーポレーテツド |
薬物送達デバイスの扉ラッチ機構
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
MX2020006639A
(es)
|
2017-12-22 |
2020-09-14 |
Regeneron Pharma |
Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
|
|
WO2019152599A1
(en)
*
|
2018-01-31 |
2019-08-08 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
|
|
BR112020013336A2
(pt)
|
2018-01-31 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
US11957745B2
(en)
|
2018-02-22 |
2024-04-16 |
Vanderbilt University |
Human Japanese Encephalitis Virus antibodies and methods of use therefor
|
|
WO2019168774A1
(en)
|
2018-02-28 |
2019-09-06 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
TW201945401A
(zh)
|
2018-03-06 |
2019-12-01 |
法商賽諾菲生物技術公司 |
降低心血管風險的方法
|
|
HUE065344T2
(hu)
|
2018-03-19 |
2024-05-28 |
Regeneron Pharma |
Mikrochip kapilláris elektroforézis assay-k és reagensek
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
TW202519260A
(zh)
|
2018-07-02 |
2025-05-16 |
美商安進公司 |
抗steap1抗原結合蛋白
|
|
CA3103681A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
|
MA53375A
(fr)
|
2018-07-24 |
2021-06-02 |
Amgen Inc |
Dispositifs d'administration pour l'administration de médicaments
|
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
US12303677B2
(en)
|
2018-07-24 |
2025-05-20 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
|
CA3103105A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
|
KR102259473B1
(ko)
|
2018-08-10 |
2021-06-02 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
|
CN119264211A
(zh)
|
2018-08-27 |
2025-01-07 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
JP7511542B2
(ja)
|
2018-08-30 |
2024-07-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質複合体を特徴づけるための方法
|
|
CN110872353B
(zh)
*
|
2018-09-03 |
2021-05-04 |
深圳华大基因科技有限公司 |
特异性结合pcsk9抗原的纳米抗体及其制备方法和应用
|
|
US20210346601A1
(en)
|
2018-09-24 |
2021-11-11 |
Amgen Inc. |
Interventional dosing systems and methods
|
|
CA3110371A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
|
EP3860685A1
(en)
|
2018-10-02 |
2021-08-11 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
|
US12151089B2
(en)
|
2018-10-05 |
2024-11-26 |
Amgen Inc. |
Drug delivery device having dose indicator
|
|
TW202541859A
(zh)
|
2018-10-15 |
2025-11-01 |
美商安進公司 |
具有阻尼機構之藥物遞送裝置及自動注射器
|
|
WO2020081480A1
(en)
|
2018-10-15 |
2020-04-23 |
Amgen Inc. |
Platform assembly process for drug delivery device
|
|
CN111110841A
(zh)
*
|
2018-10-31 |
2020-05-08 |
上海君实生物医药科技股份有限公司 |
含有抗pcsk9抗体的稳定制剂
|
|
AU2019369498A1
(en)
*
|
2018-10-31 |
2021-05-20 |
Delinia, Inc. |
Multivalent regulatory T cell modulators
|
|
EP3873563A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
MA54048A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
WO2020150491A1
(en)
|
2019-01-16 |
2020-07-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing disulfide bonds
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
AU2020263289B2
(en)
|
2019-04-24 |
2025-05-22 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
|
WO2020231992A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
EP4696320A2
(en)
|
2019-05-15 |
2026-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibody
|
|
EP3969620B1
(en)
|
2019-05-17 |
2025-06-25 |
Regeneron Pharmaceuticals, Inc. |
Genome-based methods for reducing cardiovascular risk
|
|
US12559551B2
(en)
|
2019-05-24 |
2026-02-24 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-ANGPTL3 antibodies
|
|
WO2021041067A2
(en)
|
2019-08-23 |
2021-03-04 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
|
WO2021061790A1
(en)
|
2019-09-24 |
2021-04-01 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
|
WO2021058597A1
(en)
|
2019-09-24 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject is at risk of developing arterial plaques
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
CA3158119A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
WO2021119321A1
(en)
|
2019-12-10 |
2021-06-17 |
Regeneron Pharmaceuticals, Inc. |
Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
|
|
CN115398236B
(zh)
|
2020-01-21 |
2024-06-11 |
瑞泽恩制药公司 |
用于糖基化的蛋白质的电泳的去糖基化方法
|
|
EP4192864A4
(en)
*
|
2020-08-06 |
2024-09-04 |
Stelexis Therapeutics, LLC |
IL-8 ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2022047108A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
WO2022115588A1
(en)
|
2020-11-25 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
KR20230121854A
(ko)
|
2020-12-17 |
2023-08-21 |
리제너론 파아마슈티컬스, 인크. |
단백질-캡슐화 마이크로겔의 제작
|
|
MX2023008527A
(es)
|
2021-01-20 |
2023-07-28 |
Regeneron Pharma |
Metodos para mejorar el valor proteico en cultivo celular.
|
|
JP2024512299A
(ja)
|
2021-03-03 |
2024-03-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質の粘度を定量及び変更するためのシステム及び方法
|
|
AU2022243005A1
(en)
|
2021-03-26 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
TW202313682A
(zh)
|
2021-05-18 |
2023-04-01 |
英商凱麥博有限公司 |
抗icos抗體之用途
|
|
JP2024523779A
(ja)
|
2021-05-21 |
2024-07-02 |
アムジェン インコーポレイテッド |
薬物容器用の充填レシピを最適化する方法
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
US20240316169A1
(en)
|
2021-07-05 |
2024-09-26 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
CA3230984A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Systems and methods of ph modeling and control
|
|
WO2023059803A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
|
TW202330104A
(zh)
|
2021-10-26 |
2023-08-01 |
美商再生元醫藥公司 |
用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
|
|
KR20240164561A
(ko)
|
2022-03-18 |
2024-11-19 |
리제너론 파아마슈티컬스, 인크. |
폴리펩타이드 변종을 분석하기 위한 방법 및 시스템
|
|
WO2023222854A1
(en)
|
2022-05-18 |
2023-11-23 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|
|
TW202435942A
(zh)
|
2022-12-16 |
2024-09-16 |
美商里珍納龍藥品有限公司 |
評估層析管柱完整性的方法及系統
|
|
WO2024130165A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
EP4655595A1
(en)
|
2023-01-25 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
US20240366471A1
(en)
|
2023-05-01 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
EP4688822A1
(en)
*
|
2023-05-23 |
2026-02-11 |
JLP Health GmbH |
Ldlr derived polypeptides for anti-viral uses
|
|
EP4467563A1
(en)
*
|
2023-05-23 |
2024-11-27 |
JLP Health GmbH |
Ldlr derived polypeptides for anti-viral uses
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
US20250095773A1
(en)
|
2023-09-18 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025144700A1
(en)
|
2023-12-27 |
2025-07-03 |
Absci Corporation |
Nanobody library screening using bacterial surface display
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
TW202602489A
(zh)
|
2024-03-15 |
2026-01-16 |
美商再生元醫藥公司 |
作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026030152A1
(en)
|
2024-07-29 |
2026-02-05 |
Amgen Inc. |
System and method for assessing transferability of a fill recipe
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|